PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:50 2024-07-05 EDT			5-day change	1st Jan Change
0.13 ^AUD	0.00%		+8.33%	+18.18%

07-01	PYC Therapeutics Advances Trial for Drug Candidate; Shares Up 4%	MT
06-18	Canaccord Genuity Starts PYC Therapeutics at Buy With AU$0.22 Price Target	MT

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

October 09, 2020 at 03:29 am

PYC Therapeutics Limited announced that Doug Huey will not seek re-election as a Director of the Company at the upcoming Annual General Meeting on 6 November 2020 and will step down as a director on that date.

Latest news about PYC Therapeutics Limited

PYC Therapeutics Advances Trial for Drug Candidate; Shares Up 4%	07-01	MT
Canaccord Genuity Starts PYC Therapeutics at Buy With AU$0.22 Price Target	06-18	MT
PYC Therapeutics's Fourth Neurodevelopmental Disorder Drug Candidate Moves Closer to Human Trials; Shares Up 5%	06-06	MT
PYC Therapeutics Secures US FDA Orphan Drug Designation for Eye Disease Medication Candidate; Shares Fall 4%	05-23	MT
PYC Therapeutics Completes Dosing for Eye Disease Trial; Shares Fall 5%	05-16	MT
Transcript : PYC Therapeutics Limited - Special Call	05-08
Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	04-22	MT
PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study	04-21	MT
PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	04-10	MT
PYC Therapeutics Raises AU$40 Million via Entitlement Offer	03-17	MT
PYC Therapeutics to Raise Up to AU$75 Million for Advancing Drug Candidates	03-14	MT
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-29	CI
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration	02-16	MT
Transcript : PYC Therapeutics Limited - Special Call	02-01
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%	01-01	MT
Transcript : PYC Therapeutics Limited - Shareholder/Analyst Call	11-23
Transcript : PYC Therapeutics Limited - Special Call	11-16
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease	11-13	CI
PYC Therapeutics Completes Dosing in Second Patient Cohort for Retinitis Pigmentosa Clinical Trial	11-03	MT
PYC Reports Positive Results from Preclinical Studies of Rare Eye Disease Drug	23-10-05	MT
Transcript : PYC Therapeutics Limited - Special Call	23-10-04
PYC Therapeutics Advances to Second Dose Cohort of Phase 1 Trial Following Safety Clearance	23-09-22	MT
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program	23-08-11	CI
PYC Therapeutics Raises Vision Pharma Shareholding to 96.2%	23-08-09	MT

Chart PYC Therapeutics Limited

Duration

Period

More charts

Company Profile

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PYC Therapeutics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.13 AUD

Average target price

0.275 AUD

Spread / Average Target

+111.54%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PYC THERAPEUTICS LIMITED	+18.18%	408M
MODERNA, INC.	+18.97%	44.44B
LONZA GROUP AG	+41.98%	40.03B
IQVIA HOLDINGS INC.	-10.06%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.46B
CELLTRION, INC.	-7.79%	27.29B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.29B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.8B
MEDPACE HOLDINGS, INC.	+31.28%	12.46B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research